Steroid-induced osteoporosis can be effectively treated with TeriparatideAccording to a recent study, glucocorticoid-induced osteoporosis (OP) can be effectively treated with a synthetic form of the human parathyroid hormone, Teriparatide. It was found by the involved researchers that patients with glucocorticoid-induced OP and treated with teriparatide for a period of 36 months had a greater increase in BMD (bone mineral density) and experienced fewer new vertebral fractures than patients being treated with alendronate.

The study findings were published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

From News-Medical.Net:

Glucocorticoids are steroid hormones that are naturally produced in the body or synthetically created compounds (drugs) used to reduce inflammation. These steroid drugs are used to control inflammation in patients with such autoimmune diseases as rheumatoid arthritis, systemic lupus erythematosus, and Crohn’s disease as well as inflammatory conditions such as asthma. Glucocorticoid-induced osteoporosis occurs when patients taking steroid medications such as prednisone, prednisolone, dexamethasone, and cortisone exhibit reduced bone mass and bone strength.

This 36-month, randomized, double-blind, controlled trial, led by Kenneth Saag, M.D., from the University of Alabama, was conducted at 76 centers located in 13 countries. A total of 428 patients between the ages of 22-89 with confirmed OP who had received greater than 5 mg/day of prednisone or equivalent for more than 3 months preceding screening were included. Research measures included changes in lumbar spine and hip bone, BMD, changes in bone biomarkers, fracture incidence, and safety.

Kenneth Saag, M.D., from the University of Alabama, remarked that the need of therapies for mitigating the side-effects of steroid use and improving bone mass on a substantial manner is vital.